Plus Therapeutics is a company focusing on cancer radiotherapeutics, leveraging innovative drug formulations and technologies to deliver targeted radiation doses directly to tumors. The company is in the growth stage, expanding its portfolio of therapeutic programs for both adults and children battling rare and difficult-to-treat cancers. They aim to provide a precise approach that maximizes toxicity to cancer cells while minimizing toxicity to healthy cells.

Some significant milestones in Plus Therapeutics' history include the development of a new class of targeted radiotherapeutics, leveraging Rhenium radioisotopes for precise tumor targeting, and novel drug loading techniques using nanoliposomes. The company has achieved patents for proprietary methods of transporting and trapping isotopic Rhenium for radionuclide therapy. Additionally, Plus Therapeutics has introduced innovative approaches to encapsulating radiation particles and administering elevated doses to potentially eliminate tumor cells effectively.

Plus Therapeutics has been involved in notable case studies focused on the application of their radiotherapeutic platform in treating brain and CNS cancers, including recurrent glioblastoma and leptomeningeal metastases. The company's innovative therapies have shown promising results in targeting solid organ cancers like hepatocellular carcinoma and metastatic colorectal cancer with next-generation radioembolization therapy. These case studies highlight the potential impact of Plus Therapeutics' precision cancer treatments on improving patient outcomes and quality of life.

Key events in Plus Therapeutics' history include the development and commercialization of the first Rhenium-186 radiolabeled nanoliposome therapy targeting brain and CNS cancers, as well as the introduction of the Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere for treating solid organ cancers. The company has also secured significant funding through research grants and has actively engaged in educational initiatives like patient webinars and industry summits to showcase their innovative radiotherapeutic programs. These events underscore Plus Therapeutics' commitment to advancing cancer treatment through cutting-edge technologies and strategic partnerships.